The type III capsular polysaccharide of group B streptococci (GBS) consists of a linear backbone with short side chains ending in residues of N-acetylneuraminic acid, or sialic acid. The presence of sialic acid on the surface of the organism inhibits activation of the alternative pathway of complement and is thought to be an important element in the virulence function of the capsule. We showed previously that a mutant strain of GBS that expressed a sialic acid-deficient, or asialo, form of the type III polysaccharide was avirulent, supporting a virulence function for capsular sialic acid. We now report the derivation of an asialo capsule mutant from a highly encapsulated wild-type strain of type III GBS, strain COH1, by insertional mutagenesis with transposon Tn916AE. In contrast to the wild-type strain, the asialo mutant strain COHl-11 was sensitive to phagocytic killing by human leukocytes in vitro and was relatively avirulent in a neonatal rat model of GBS infection. The asialo mutant accumulated free intracellular sialic acid, suggesting a defect subsequent to sialic acid synthesis in the biosynthetic pathway leading to capsule sialylation. The specific biosynthetic defect in mutant strain COHl-11 was found to be in the activation of free sialic acid to CMP-sialic acid: CMP-sialic acid synthetase activity was present in the wild-type strain COH1 but was not detected in the asialo mutant strain COHl-11.
The type III capsular polysaccharide of group B streptococci (GBS) consists of a linear backbone with short side chains ending in residues of N-acetylneuraminic acid, or sialic acid. The presence of sialic acid on the surface of the organism inhibits activation of the alternative pathway of complement and is thought to be an important element in the virulence function of the capsule. We showed previously that a mutant strain of GBS that expressed a sialic acid-deficient, or asialo, form of the type III polysaccharide was avirulent, supporting a virulence function for capsular sialic acid. We now report the derivation of an asialo capsule mutant from a highly encapsulated wild-type strain of type III GBS, strain COH1, by insertional mutagenesis with transposon Tn916AE. In contrast to the wild-type strain, the asialo mutant strain COHl-11 was sensitive to phagocytic killing by human leukocytes in vitro and was relatively avirulent in a neonatal rat model of GBS infection. The asialo mutant accumulated free intracellular sialic acid, suggesting a defect subsequent to sialic acid synthesis in the biosynthetic pathway leading to capsule sialylation. The specific biosynthetic defect in mutant strain COHl-11 was found to be in the activation of free sialic acid to CMP-sialic acid: CMP-sialic acid synthetase activity was present in the wild-type strain COH1 but was not detected in the asialo mutant strain COHl-11.
One of the two transposon insertions in the asialo mutant COHl-11 mapped to the same chromosomal location as one of the two Tn916 insertions in the previously reported asialo mutant COH31-21, identifying this site as a genetic locus necessary for expression of CMP-sialic acid synthetase activity. These studies demonstrate that the enzymatic synthesis of CMP-sialic acid by GBS is an essential step in sialylation of the type III capsular polysaccharide.
Group B streptococci (GBS) are the leading cause of neonatal sepsis and meningitis in the United States (4, 13) . Several lines of evidence indicate that the GBS capsular polysaccharide is a critical factor in the ability of the organism to produce invasive infection. While the four major capsular types are found with similar frequencies among isolates cultured as commensals from the genital tracts of colonized women, type III strains predominate among isolates from the blood or cerebrospinal fluid of infants with GBS sepsis. Organisms of capsular type III account for approximately 60% of GBS isolated from infants with neonatal sepsis and 80 to 90% of those with meningitis (1, 6) . That type III strains are disproportionately prevalent among GBS associated with invasive disease suggested that the type III capsule serves as a virulence factor. This hypothesis was supported by the observation that type III isolates from the blood or cerebrospinal fluid of ill infants were more highly encapsulated than were colonizing strains (16) . More direct evidence for the role of the type III capsule in virulence came from our studies of an unencapsulated mutant strain of type III GBS: loss of capsule expression was associated with loss of virulence in a neonatal rat model of GBS infection (26) .
A structural feature of the type III capsule that appears to be important in virulence is the presence of N-acetylneuraminic acid, or sialic acid. The type III capsular polysaccharide is a high-molecular-weight polymer with a trisaccharide backbone repeating unit. Attached to each backbone repeating unit is a disaccharide side chain which * Corresponding author.
terminates with a sialic acid residue (38) . The presence of these externally located sialic acid residues on the surface of the GBS cell has important implications for interaction of the organism with the host immune system. Sialic acid plays a major role in determining the conformation of the epitope recognized by protective anticapsular antibodies (14) . In addition, like other sialic acid-coated particles, fully encapsulated type III GBS inhibit activation of the alternative pathway of complement. Several investigators have shown that surface-located sialic acid residues increase the affinity of surface-bound C3b for the complement regulatory protein factor H, resulting in the inactivation of C3b by factor I, rather than amplification of alternative pathway activity (10, 21) . The sialic acid-containing capsular polysaccharides of both Escherichia coli Kl and GBS type III have been shown to inhibit complement activation by this mechanism, accounting, at least in part, for the resistance of these organisms to phagocytic killing in the absence of specific antibody (7, 8, 31) .
Chemical or enzymatic removal of the sialic acid residues from the GBS type III polysaccharide produces the desialylated or core type III polysaccharide, which has a repeating unit structure and immunoreactivity identical to those of the capsular polysaccharide of type 14 Streptococcus pneumoniae (14, 15, 38) . We recently reported the derivation and characterization of a transposon mutant strain of type III GBS that expressed the core, or asialo, form of the GBS type III capsular polysaccharide (39) . Loss of capsular sialic acid was associated with a similar reduction in virulence as complete loss of capsule, supporting a critical role of sialic acid in the virulence function of the type III capsule (39) .
The wild-type GBS strain COH31r/s from which we derived the asialo mutant reported previously was relatively poorly encapsulated. Since most type III GBS strains isolated from ill infants express larger amounts of capsular polysaccharide than strain COH31r/s, mutants derived from strain COH31r/s provided a useful, but limited, experimental model. To investigate more thoroughly the effects of altered capsule expression on virulence, and also to begin to dissect the molecular mechanisms of capsule biosynthesis and regulation, we developed a system for derivation of capsule mutants in the background of the well-encapsulated type III GBS strain COHi, a wild-type isolate typical of those associated with neonatal sepsis. In contrast to strain COH31r/s, COHi is relatively resistant to phagocytic killing in the absence of specific antibody and is more virulent in animals than strain COH31r/s.
We now report the derivation of an asialo capsule mutant from the well-encapsulated wild-type strain of type III GBS, strain COHi, by insertional mutagenesis with transposon Tn9J6AE. Comparison of the asialo mutant with the wildtype strain in assays of virulence, both in vitro and in vivo, supported the hypothesis that the sialylated type III capsule is a virulence factor for GBS. These investigations defined an essential enzymatic step in sialylation of the type III GBS polysaccharide and identified a genetic locus required for expression of this enzymatic activity in a region of the GBS chromosome previously implicated in capsule biosynthesis.
MATERIALS AND METHODS
Antigens and antisera. Purified type III GBS capsular polysaccharide was prepared from broth cultures of type III GBS strain M781 as previously described (37) . Type 14 pneumococcal (Pnl4) polysaccharide was prepared by Merck Sharpe & Dohme, Inc., and obtained through the American Type Culture Collection, Rockville, Md. Type III GBS antiserum was prepared by immunizing New Zealand White rabbits with formalin-fixed type III GBS organisms (8) . Pnl4 antiserum was purchased from Dako Corporation, Santa Barbara, Calif. A murine monoclonal antibody (UU218) specific for the native type III GBS polysaccharide (27) was used to identify capsule-deficient mutants in immunoblot assays. This reagent was kindly provided by Harry Hill, University of Utah, Salt Lake City.
Bacterial strains and plasmids. Bacterial strains and plasmids used in this study are described in Table 1 .
Isolation of mutants. Tn916AE is a derivative of transposon Tn9J6 in which the tetracycline resistance gene has been replaced with a constitutive erythromycin resistance gene (25) . Conjugation of Tn916AE from Enterococcus faecalis RH110 to type III GBS strain COH1 was performed as described previously (25) . Transconjugants obtained after filter mating were enriched for mutants deficient in expression of capsule or capsular sialic acid by their failure to agglutinate in the presence of wheat germ lectin (26) and were selected by growth on Todd-Hewitt agar containing tetracycline (10 ,ug/ml) (to select for GBS) and erythromycin (10 ,ug/ml) (to select for Tn9J6AE).
Immunoblot analysis. Immunoblot analysis of transconjugants was performed as described previously (26) . Briefly, colonies were transferred from agar plates to nitrocellulose filters, and the bacterial cells were lysed and precipitated. Filters were treated with diluted antiserum or with monoclonal antibody UU218 and then with the appropriate alkaline phosphatase-conjugated second antibody, and color development was achieved with 5-bromo-4-chloro-indolyl-phos- (26) . The 32P-Tn9J6AE probe was prepared from the 20.1-kb EcoRI fragment of plasmid pCER110. This fragment was electroeluted from low-melting-temperature agarose and labeled with [32P]deoxynucleotides in vitro by random priming hexamer labeling (Pharmacia-LKB Biotechnology, Uppsala, Sweden). The Tn916AE insertion sites in COHl-11 were mapped as described previously (18) . The EcoRI fragments flanking each of the two Tn916 insertion sites in the genome of COH31-21 have been cloned previously and designated pCER3121-1 and pCER212-1, respectively (Table 1) (18) . Plasmid pCER3121-1 contains a 7.5-kb EcoRI fragment that was mapped to the 30-kb region of the GBS chromosome associated with type III capsule production. Plasmid pCER212-1 contains the 1.0-kb fragment that flanked the second Tn9J6 insertion site in COH31-21, a site remote from the 30-kb capsule region. DNA from each of these two cloned fragments was used to prepare probes to determine whether the two Tn9J6AE sequences in COHl-11 were in the same chromosomal locations as the Tn916 insertions in COH31-21.
Purification of capsular polysaccharide from strain COHl-11. Strain COHl-11 was grown in 80 liters of Todd-Hewitt broth containing 8% glucose with continuous titration to pH 7.0. Capsule was released from the bacterial cells by using mutanolysin as described previously (39) . The crude capsular polysaccharide was purified by chromatography on DEAE-Sephacel as described previously (39) . The polysaccharide was detected in the eluate which failed to bind to the DEAE column by reactivity in Ouchterlony immunodiffusion gels with Pnl4 antiserum (20) . The fractions containing VOL. 60, 1992 on October 20, 2017 by guest http://iai.asm.org/ Downloaded from polysaccharide were dialyzed extensively against distilled water and lyophilized. Contaminating group B carbohydrate was depolymerized by treatment with 0.5 M NaOH at 50°C for 48 h; because base treatment may result in partial deacetylation of N-acetylglucosamine residues, the NaOHtreated capsular polysaccharide was re-N-acetylated with acetic anhydride (4% by volume) in 5% sodium bicarbonate at room temperature for 2 h. After dialysis and lyophilization, the final product was separated from low-molecularweight contaminants by chromatography on a column (1.6 by 82 cm) of Sepharose 4B-CL with 20 mM Tris buffer (pH 7.2) as the eluant. The final product was shown to contain less than 1% protein by the Bradford method (5), with bovine serum albumin (Sigma Chemical Co., St. Louis, Mo.) as a standard. Sialic acid content was estimated by the thiobarbituric acid method (34), using sialic acid (Sigma) as a standard.
Determination of molecular size of COHl-li and COH1 polysaccharides by fast protein liquid chromatography. Each strain was grown to the logarithmic phase in 2 liters of Todd-Hewitt broth (A650 = 0.5). The bacterial cells were collected by centrifugation and washed once with 50 mM Tris-HCl buffer (pH 7.6). The cell pellet was resuspended in 100 ml of the same buffer containing 40% (wt/vol) sucrose and treated with mutanolysin (4 mg; Sigma) for 12 h at 37°C to release capsular polysaccharide from the cells. Protoplasts and cell debris were removed by centrifugation at 12,000 x g for 20 min, and then the cell capsule extract was treated with DNase (5 ,ug/ml; Sigma) and RNase (20 ,ug/ml; Sigma) for 8 h at 37°C and then with pronase (40 ,ug/ml; Sigma) for 16 h at 37°C. After dialysis against water, the polysaccharide was lyophilized, dissolved in 50 mM TrisHCl buffer (pH 7.6), and loaded onto a column (2.6 by 85 cm) of Sephacryl S300 (Pharmacia). Fractions containing capsular polysaccharide were identified by testing aliquots in enzyme-linked immunosorbent assay (ELISA) inhibition as described previously (35) . Type III GBS ELISA was used to detect COH1 polysaccharide, and Pnl4 ELISA was used to detect COHl-11 polysaccharide. Fractions containing polysaccharide by ELISA were pooled, dialyzed against water, and lyophilized. The polysaccharide was dissolved in phosphate-buffered saline and loaded onto a Superose 6 HR 10/30 column (Pharmacia) with phosphate-buffered saline as the running buffer at a flow rate of 0.5 ml/min. Elution of the polysaccharide was monitored by measuring the refractive index of the eluate (model R401 Refractometer; Waters Associates, Bedford, Mass.), and the elution volume of each polysaccharide was confirmed by ELISA inhibition as described above. The molecular size of each polysaccharide was estimated by comparison of its Ka. with a calibration curve generated by using dextran standards.
ELISA. GBS III or Pnl4 capsular polysaccharide was coupled to poly-L-lysine (Sigma) and coated onto 96-well plates as previously described at a concentration of 1 ,ug of polysaccharide per ml (11, 26) . After washing three times with 40 mM sodium phosphate (pH 7.0) containing 0.05% Tween 20 (Sigma), nonspecific protein-binding sites were blocked by incubating wells with 200 ,ul of 5% skim milk powder (Difco) in the same buffer at 37°C for 2 h. After washing three times with the same buffer, inhibitor and antiserum were added at an appropriate dilution in the same buffer and incubated at 37°C for 1 h. Subsequent steps of addition of alkaline phosphatase-conjugated secondary antibody, addition of substrate, and measurement of color development were done as described previously (26) .
In vitro opsonophagocytic assay. Opsonophagocytic assays were performed essentially as described by Baltimore et al. (2) . Early log-phase organisms (4 x 106 CFU) were incubated with 3 x 106 human peripheral blood leukocytes in 0.5 ml of Eagle's minimal essential medium. Each assay contained, in addition, 10% human serum (previously adsorbed with GBS type III organisms and stored at -80°C to preserve complement activity). Aliquots were removed, diluted in sterile water, and spread on blood agar plates for quantitative culture at time zero and after 1 h of end-over-end rotation at 37°C. Virulence assays. The virulence of mutant strain COHl-1l was compared with that of the wild-type strain COH1 in a neonatal rat model of lethal GBS infection as described previously (26) . The 50% lethal dose (LD50) was calculated by the method of Reed and Meunch (23) based on data from two experiments utilizing a total of 80 animals for each strain.
Assay for intracellular sialic acid. GBS strains to be tested for the presence of free intracellular sialic acid were grown in 500 ml of Todd-Hewitt broth to the mid-log phase (A650 = 0.5 to 0.8). Bacterial cells were collected by centrifugation, suspended in 5 ml of 10 mM Tris (pH 7.0) containing mutanolysin (3,000 U/ml; Sigma), and incubated at 37°C for 1 h. The cells were ruptured by shaking with glass beads for 20 min (Vibrogen cell mill; Edmund Buhler, Tubingen, Germany). The lysate was clarified by centrifugation at 13,600 x g for 5 min (Micro-centrifuge; Fisher Scientific Co., Pittsburgh, Pa.). Nucleic acids were removed by precipitation with 60% ethanol, and the supernatant was analyzed by thin-layer chromatography (TLC) on plastic-backed plates of Silica Gel 60 (E. Merck AG, Darmstadt, Germany). Plates were developed in a solvent system of butanol-acetic acidwater (2:1:1, vol/vol), dried, and stained with diphenylamine spray. Sialic acid (N-acetylneuraminic acid) was identified by Rf and characteristic pink staining by comparison with an authentic sialic acid standard run simultaneously.
Purification of sialic acid from strain COHl-li. Asialo mutant strain COHl-11 was grown in broth culture as described above. Lyophilized bacterial cells (10 g) were stirred at 37°C overnight in 250 ml of water containing 1 mM MgCl2 and 50,000 U of mutanolysin. The protoplasts were recovered by centrifugation and lysed by sonication in water for 15 min (Sonifier; Heat Systems-Ultrasonics, Inc., Plainview, N.Y.). An equal volume of 95% ethanol was added to the lysate and allowed to stand at 4°C overnight. Precipitate and cell debris were removed by centrifugation, and the supernatant was dried on a rotary evaporator (Rotavapor; Buchl, Flawil, Switzerland). Sialic acid was purified from this material by a modification of the method described by Pozsgay et al. (22) for purification of sialic acid from edible bird's nest. Briefly, the residue was dissolved in 3 ml of water and loaded onto a column (2.6 by 18 cm) containing Dowex AG-50W-X8 cation-exchange resin, equilibrated with water. Fractions corresponding to the void volume were lyophilized, redissolved in 3 ml of water, and loaded onto a column (2.6 by 16 cm) containing Dowex AG 2-X8 anion-exchange resin, 100/200 mesh, chloride form. The sample was eluted with a 500-ml linear gradient of 0.2 to 0.5 M formic acid in water. Fractions were analyzed by TLC for the presence of substances resembling sialic acid by Rf and staining characteristics. Fractions in which sialic acid was detected by TLC were pooled, and formic acid was removed by repeated evaporation on a rotary evaporator. The final product was desalted on a column (1.6 by 80 cm) of P2 Bio-Gel, using water as the running buffer.
CMP-sialic acid synthetase assay. GBS cells from a mid- (Fig. 1) . The 1.3-kb probe from COH31-21 hybridized to a 7.5-kb EcoRI fragment in COH31r/s and to a corresponding 9.0-kb fragment in COHi (Fig. 1) . These results were anticipated because COHi was shown previously to lack an EcoRI site present in COH31r/s in this region (Fig. 3) (18) . The (Fig. 4) . The same COHl-11 extract produced dosedependent inhibition of the reaction between Pnl4 antiserum and Pnl4 polysaccharide, consistent with the identification of the mutant capsule as the core or asialo GBS type III polysaccharide (Fig. 5 ).
This conclusion was further supported by studies characterizing the mutant capsular polysaccharide purified from strain COHl-11. The COHl-11 polysaccharide was isolated from a mutanolysin extract of the bacterial cells and purified by ion-exchange and gel filtration chromatography. sponding to an Mr of -100,000, somewhat smaller than the apparent molecular size of the native polysaccharide purified from COH1 (Kav = 0.38, Mr of -250,000), although both polysaccharides eluted as broad peaks, indicating substantial variation in chain length.
We also attempted to quantify the amount of capsular polysaccharide produced by the asialo mutant strain COHl-11 compared with the wild-type strain COH1, reasoning that a defect in sialylation of the polysaccharide might affect the efficiency of assembly or export of the polysaccharide, either directly or because of inhibitory effects of intracellular accumulation of one or more biosynthetic intermediates. To quantify capsule production by mutant and parent strains in the same immunoassay system, we treated cells of the wild-type strain COH1 with neuraminidase to remove sialic acid from the capsule and then compared capsule extracts of the asialo mutant strain COHl-11 and neuraminidase-treated COH1 for inhibitory capacity in the Pnl4 ELISA. The amount of polysaccharide extracted from each strain was quantified by comparison with a standard curve generated with authentic Pnl4 polysaccharide. We detected the equivalent of 1.1 jxg of Pnl4 polysaccharide per 109 CFU of the parent strain COH1 and 0.041 ,ug/109 CFU of the asialo mutant strain COHl-1l. We have shown previously that the affinity of antibody binding to the Pnl4 polysaccharide increases with the chain length of the polysaccharide (36) . However, the relatively small difference in molecular size of the COHl-li versus COH1 polysaccharides is unlikely to account for a difference of 25-fold in the ELISA measurement of COHl-1l versus desialylated COH1 polysaccharide. The 25-fold difference in immunoreactivity probably reflects some diminution in affinity of antibody binding to the shorter-chain-length polysaccharide of COHl-11 as well as a reduction in the number of polysaccharide molecules produced. These results indicate that the capsular polysaccharide produced by the asialo mutant COHl-11 not only lacked sialic acid but also was reduced in amount compared with the wild-type strain.
Effect of altered capsule expression on virulence of mutant strain COHl-11. We reported previously that loss of capsular sialic acid in mutant strain COH31-21 was associated with diminished virulence in a neonatal rat model of GBS infec- tion, comparable to the reduction in virulence associated with complete loss of capsule (26, 39) . We observed a similar loss of virulence in the asialo mutant strain COHl-11 compared with wild-type strain COHl: the LD50 for mutant strain COHl-11 was greater than 1 x 107 CFU/g of body weight compared with 1.1 x 102 CFU/g for wild-type strain COHL.
The ability of the sialic acid-rich type III capsule to inhibit complement-mediated opsonophagocytic killing is thought to be an important virulence mechanism for GBS (7) . Therefore, we examined resistance to phagocytic killing in vitro of the asialo mutant strain COHl-11. The parent strain COH1 is relatively resistant to phagocytosis in the absence of specific antibody. We observed no change in CFU of strain COH1 after 1 h of incubation with 10% normal human serum (as a complement source) and human peripheral blood leukocytes. In contrast, incubation of the mutant strain COHl-11 under the same conditions resulted in a >95% decrease in CFU ( Table 2 ). The reduced virulence of strain COHl-11, both in neonatal rats and in the opsonophagocytic assay, may be attributable not only to the absence of capsular sialic acid but also to the diminished level of capsule production in this strain.
Characterization of biosynthetic defect in asialo mutant strain COHl-11. The absence of sialic acid in the capsular polysaccharide of COHl-11 could be due to a defect in any of several steps in the biosynthetic pathway of the native sialylated type III polysaccharide, including synthesis of sialic acid, formation of an activated precursor, or transfer of sialic acid from activated precursor to the polysaccharide or to an intermediate acceptor molecule. While the details of this pathway are unknown in GBS, these general steps are likely to be involved, based on analogous biosynthetic schemes in other bacteria (30) . As a first step in identifying the specific defect in COHI-11, we examined the asialo mutant COHl-11 and wild-type strain COHi for the presence of free intracellular sialic acid. While the presence of interfering substances did not permit accurate quantitation by colorimetric methods, sialic acid was readily identified by TLC analysis of lysates of mutant strain COHl-11 and was not seen in lysates of COHL. The sialic acid band was identified by Rf value and characteristic bright pink staining with diphenylamine spray (Fig. 6) Jennings, National Research Council of Canada, Ottawa, Ontario) confirmed it to be authentic sialic acid; the minor product corresponding to the faster-migrating band visualized by TLC was identified as a lactone form, i.e., an internal ester, of sialic acid. This latter species probably represents a degradation product which arose either in the cells as a result of the abnormal accumulation of sialic acid or during the extraction and purification procedures.
The asialo mutant strain accumulated free sialic acid, suggesting that synthesis of sialic acid was intact but that a subsequent step in the biosynthetic pathway was blocked. Synthesis by E. coli of the poly-sialic acid Kl capsular polysaccharide proceeds from synthesis of free sialic acid to activation of sialic acid by the action of CMP-sialic acid synthetase. The activated precursor molecule, CMP-sialic acid, then serves as the substrate for the transfer of sialic acid to an acceptor molecule, from which it is incorporated into the growing sialic acid polymer (24, 30) . On the basis of the E. coli Kl system, we reasoned that the likely defect in mutant strain COHl-11 was in the activation of sialic acid to a nucleotide precursor molecule. To test this hypothesis, we developed an assay for CMP-sialic acid synthetase activity in GBS. The use of 32P-labeled CTP as the substrate in this assay increased the sensitivity over that obtained by using the thiobarbituric acid assay for detection of CMP-sialic acid and allowed us to specifically identify the enzymatic product as CMP-sialic acid, rather than another sialic acid-containing compound. After incubation, the assay mixture was analyzed by TLC and autoradiography: [32P]CMP-sialic acid was identified on the autoradiogram by its comigration with a CMP-sialic acid standard. Incubation of lysates of the wild-type strain COHi with sialic acid and [32P]CTP resulted in incorporation of the label into the band corresponding to CMP-sialic acid (Fig. 7) . No incorporation was observed when sialic acid was omitted or when the cell lysate was boiled, indicating that the reaction required both sialic acid as a substrate and a heat-labile factor in the cell lysate, presumably CMP-sialic acid synthetase. CMP-sialic acid synthetase activity was not detected in lysates of the asialo mutant COHl-11 (Fig. 7) . The absence of CMP-sialic acid synthetase activity in the asialo mutant strain COHl-11, together with evidence of intracellular accumulation of the enzyme's substrate, free sialic acid, implicates this enzymatic step as the site of the biosynthetic defect in sialylation 1 of the COHl-11 polysaccharide. These experiments identify the activation of sialic acid to CMP-sialic acid as a required step in synthesis of the native type III polysaccharide.
DISCUSSION
The type III capsular polysaccharide of GBS has been shown to be an important virulence determinant (1, 6, 16, 26) . The presence of sialic acid residues on the surface of the organisms inhibits activation of the alternative pathway of complement. Type III GBS from which sialic acid was removed by treatment with neuraminidase activated the alternative pathway, leading to efficient phagocytosis of the desialylated bacteria (7) . The importance of the sialic acidrich type III capsule in virulence was supported by our previous studies of capsule-deficient mutants derived from the type III GBS strain COH31r/s. In those studies, loss of encapsulation or loss of capsule sialylation was associated with reduced virulence of the organisms in animals (26, 39) .
We now report the derivation and characterization of a mutant strain with an asialo capsular phenotype, as we described previously (39) ; the new mutant, however, was derived from the well-encapsulated type III GBS strain COHi, typical of strains isolated from neonates with GBS sepsis. In contrast to poorly encapsulated type III strains, strains such as COHi are relatively resistant to phagocytic killing in vitro in the absence of type-specific antibody (2, 8) . Loss of capsular sialic acid in the mutant strain COHl-11 was associated with loss of resistance to phagocytic killing in vitro and with decreased virulence in vivo. However, these changes in the virulence characteristics of the asialo mutant COHl-11 may reflect not only loss of capsular sialic acid but also a quantitative reduction in the capsule expression. Since poorly encapsulated wild-type strains of type III GBS also have diminished resistance to phagocytosis, at least part of the reduced virulence of strain COHl-11 may be a result of its smaller amount of capsule compared with the parent strain. virulence has been established, little is known at the genetic or biochemical level about the synthesis or regulation of the GBS capsular polysaccharide. On the basis of the biosynthetic pathways of extracellular polysaccharides produced by other bacteria, we presume that synthesis of the GBS capsule must be complex, involving transport into the cell and/or synthesis of the four component sugars, activation of each to a nucleotide precursor, the coordinated transfer of each sugar, in sequence, to the repeating unit oligosaccharide, polymerization, export, and attachment of the polysaccharide to the cell surface (24, 30) . The identification of a mutant strain of type III GBS deficient specifically in capsular sialic acid has allowed us to begin to dissect the portion of the capsule biosynthesis pathway involved in sialylation of the type III polysaccharide. In E. coli, the following basic scheme comprises the major biosynthetic steps for synthesis and polymerization of sialic acid to form the Kl capsular polysaccharide (24, 30) : Our finding of increased amounts of free intracellular sialic acid in mutant strain COHl-11, which expressed the asialo capsular polysaccharide, suggested that sialic acid synthesis was intact and that the block was at a later step in the pathway, e.g., in the activation of sialic acid to a nucleotidesugar precursor. CMP-sialic acid synthetase activity was not detected in the asialo mutant strain COHl-11 but was readily demonstrated in the wild-type strain. Thus, the formation of CMP-sialic acid by CMP-sialic acid synthetase appears to be an essential step in sialylation of the type III GBS capsular polysaccharide. How the reduction in total capsule expression in COHl-11 is related to the specific defect in sialylation is not yet known; the mechanisms for polymerization or export of the polysaccharide may be less efficient for the asialo form, as suggested by the shorter chain length of the COHl-11 polysaccharide; accumulation of free intracellular sialic acid may down-regulate other steps in capsule biosynthesis by feedback inhibition or as a nonspecific toxic effect; or the mutation(s) in COHl-11 may have more general effects in regulating capsule expression.
The asialo mutants COH31-21 and COHl-11, derived from different type III wild-type strains, both had two transposon insertions, one of which, in each case, was located at the same chromosomal location in a region involved in capsule biosynthesis (18 (3, 9, 12, 17, 28, 29, 33) . Further studies are needed to define more precisely the location and function of the genes controlling GBS capsule synthesis. These investigations represent a first step in understanding the biosynthesis and regulation of capsular polysaccharide production by this important human pathogen.
